190 Results

People

  1. Saltz
    Saltz
  2. Kelsen
    Kelsen
  3. Bajorin
    Bajorin
  4. O'Reilly
    O'Reilly
  5. Abrey
    Abrey
  6. Marks
    Marks
  7. Aghajanian
    Aghajanian
  8. Ilson
    Ilson
  9. De Angelis
    De Angelis
  10. Kelly
    Kelly

Groups

  1. Department of Medicine (143)
  2. Solid Tumor Oncology Division (115)
  3. Gastrointestinal Oncology Service (39)
  4. Epidemiology and Biostatistics (31)
  5. Biostatistics Service (29)
  6. Center for Pancreatic Cancer Research (29)
  7. Hematologic Malignancies, Division of (29)
  8. Survivorship Research (27)
  9. Genitourinary Oncology Service (25)
  10. Surgery (25)
  1. "dehydration"
Formats
  1. Journal Article (185)
  2. Review (2)
  3. Book Section (1)
  4. Conference Paper (1)
  5. Editorial (1)
Groups
  1. Department of Medicine (143)
  2. Solid Tumor Oncology Division (115)
  3. Gastrointestinal Oncology Service (39)
  4. Epidemiology and Biostatistics (31)
  5. Biostatistics Service (29)
  6. Center for Pancreatic Cancer Research (29)

More Groups

People
  1. Leonard Saltz (12)
  2. David Kelsen (10)
  3. Dean Bajorin (9)
  4. Eileen O'Reilly (9)
  5. Lauren Abrey (8)
  6. Paul Marks (8)

More People

Years
  1. 2025 (1)
  2. 2024 (11)
  3. 2023 (7)
  4. 2022 (2)
  5. 2021 (6)
  6. 2020 (11)

More Years

Publications
  1. Cancer (17)
  2. Journal of Clinical Oncology (16)
  3. Lancet Oncology (14)
  4. Gynecologic Oncology (10)
  5. Investigational New Drugs (10)
  6. Clinical Cancer Research (9)

More Publications

Publishers
  1. Elsevier Inc. (31)
  2. Springer (21)
  3. Wiley Blackwell (20)
  4. American Society of Clinical Oncology (16)
  5. Elsevier Science, Inc. (16)
  6. Oxford University Press (16)

More Publishers

Results (190)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
    Journal Article

    Gluck, W. L.; Gounder, M. M.; Frank, R.; Eskens, F.; Blay, J. Y.; Cassier, P. A.; Soria, J. C.; Chawla, S.; de Weger, V.; Wagner, A. J.; more...
    Investigational New Drugs (2020)

    Fulltext@MSK | Save
  • Bendamustine with dexamethasone in relapsed/ refractory systemic light-chain amyloidosis: Results of a phase II study
    Journal Article

    Lentzsch, S.; Lagos, G. G.; Comenzo, R. L.; Zonder, J. A.; Osman, K.; Pan, S.; Bhutani, D.; Pregja, S.; Sanchorawala, V.; Landau, H.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: The ANNOUNCE randomized clinical trial
    Journal Article

    Tap, W. D.; Wagner, A. J.; Schöffski, P.; Martin-Broto, J.; Krarup-Hansen, A.; Ganjoo, K. N.; Yen, C. C.; Abdul Razak, A. R.; Spira, A.; Kawai, A.; more...
    JAMA - Journal of the American Medical Association (2020)

    Fulltext@MSK | Save
  • Phase I study of trifluridine/tipiracil plus irinotecan and bevacizumab in advanced gastrointestinal tumors
    Journal Article

    Varghese, A. M.; Cardin, D. B.; Hersch, J.; Benson, A. B.; Hochster, H. S.; Makris, L.; Hamada, K.; Berlin, J. D.; Saltz, L. B.
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Journal Article

    Shapiro, G. I.; LoRusso, P.; Kwak, E.; Pandya, S.; Rudin, C. M.; Kurkjian, C.; Cleary, J. M.; Pilat, M. J.; Jones, S.; de Crespigny, A.; more...
    Investigational New Drugs (2020)

    Fulltext@MSK | Save
  • Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1-2 trials
    Journal Article

    Drilon, A.; Siena, S.; Dziadziuszko, R.; Barlesi, F.; Krebs, M. G.; Shaw, A. T.; de Braud, F.; Rolfo, C.; Ahn, M. J.; Wolf, J.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials
    Journal Article

    Doebele, R. C.; Drilon, A.; Paz-Ares, L.; Siena, S.; Shaw, A. T.; Farago, A. F.; Blakely, C. M.; Seto, T.; Cho, B. C.; Tosi, D.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer
    Journal Article

    Moore, K. N.; Miller, A.; Bell-McGuinn, K. M.; Schilder, R. J.; Walker, J. L.; O'Cearbhaill, R. E.; Guntupalli, S. R.; Armstrong, D. K.; Hagemann, A. R.; Gray, H. J.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer
    Journal Article

    Higano, C. S.; Armstrong, A. J.; Sartor, A. O.; Vogelzang, N. J.; Kantoff, P. W.; McLeod, D. G.; Pieczonka, C. M.; Penson, D. F.; Shore, N. D.; Vacirca, J.; more...
    Cancer (2019)

    Fulltext@MSK | Save
  • Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: The phase II GATHER study
    Journal Article

    Sharman, J. P.; Forero-Torres, A.; Costa, L. J.; Flinn, I. W.; Inhorn, L.; Kelly, K.; Bessudo, A.; Fayad, L. E.; Kaminski, M. S.; Evens, A. M.; more...
    Leukemia and Lymphoma (2019)

    Fulltext@MSK | Save